Adaptimmune Therapeutics (ADAP) has shared an update.
Adaptimmune Therapeutics plc has announced the appointment of Cintia Piccina as Chief Commercial Officer, commencing March 18, 2024, with a base salary of $460,000 and eligibility for a 45% annual bonus based on company performance and board-established criteria. Additionally, Piccina is entitled to business expense reimbursement, a relocation payment, and participation in equity plans, with specific vesting schedules for market value and RSU-style share options. Her employment agreement includes standard termination, severance, non-competition, and confidentiality terms, reflecting her extensive experience in the life sciences sector with companies like AlloVir and Novartis.
For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.
